The Center for Biosimilars® recaps the top 5 stories in biosimilars news for the week of November 13.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of November 13.
Number 5: Intragovernmental organization The South Centre has released a paper that calls on regulatory bodies to approve “biological generics” rather than biosimilars.
Number 4: At the SMi Biosimilars North America 2017 conference, a Mylan executive warned that reference product sponsors may be involved in a “whisper campaign” against biosimilars.
Number 3: A recent review identified patient-, disease-, and treatment-related factors that may predict response to anti—tumor necrosis factor therapies.
Number 2: Contributor Sonia T. Oskouei breaks down the key facts that biosimilar stakeholders need to know about CMS’ recent change in biosimilar reimbursement policy.
Number 1: Two major biosimilar patent litigation cases came to a close in recent days, with the ruling Amgen v Apotex upheld in an appellate court, and with Janssen dropping its suit against biosimilar developer Samsung Bioepis.
To read all of these articles and more, visit centerforbiosimilars.com.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.